A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2018
Price : $35 *
At a glance
- Drugs HI-con1 (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Proof of concept; Therapeutic Use
- Acronyms DECO
- Sponsors Iconic Therapeutics
- 07 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Mar 2018 Status changed from not yet recruiting to recruiting.
- 07 Mar 2018 New trial record